Get started
Author

Rakesh Kumar

COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer
2022 · Roy S. Herbst, Margarita Majem, et al. · Journal of Clinical Oncology · 317
PDF
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
2008 · Takuya Osada, Gabriel Chong, et al. · Cancer Immunology Immunotherapy · 312
Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
2009 · R Kumar, M-C Crouthamel, et al. · British Journal of Cancer · 218
PDF
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer
2018 · Charu Aggarwal, Roger B. Cohen, et al. · Clinical Cancer Research · 148
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
2023 · Tina Cascone, Gozde Kar, et al. · Cancer Discovery · 142
PDF
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
2024 · Benjamin Besse, Elvire Pons-Tostivint, et al. · Nature Medicine · 140
PDF
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors
2023 · Johanna Bendell, Patricia LoRusso, et al. · Cancer Immunology Immunotherapy · 132
PDF
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
2022 · Emerson A. Lim, Johanna C. Bendell, et al. · Clinical Cancer Research · 90
Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc).
2018 · Michael J. Overman, Patricia LoRusso, et al. · Journal of Clinical Oncology · 75
Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
2020 · Ani S. Balmanoukian, Jeffrey R. Infante, et al. · Clinical Cancer Research · 57
PDF
Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2022 · Charu Aggarwal, Nabil F. Saba, et al. · Clinical Cancer Research · 54
A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer
2020 · Yasmin Hasan, Larissa Furtado, et al. · International Journal of Radiation Oncology*Biology*Physics · 54
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors
2020 · Lillian Siu, Joshua Brody, et al. · Journal for ImmunoTherapy of Cancer · 51
PDF
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial
2025 · Tina Cascone, Laura Bonanno, et al. · Nature Medicine · 50
PDF
Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).
2021 · Johanna C. Bendell, Patricia LoRusso, et al. · Journal of Clinical Oncology · 39
A Prospective Randomized Study Comparing Two Techniques of Perioperative Blood Conservation: Isovolemic Hemodilution and Hypervolemic Hemodilution
2002 · Rakesh Kumar, Indranil Chakraborty, et al. · Anesthesia & Analgesia · 37
A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
2024 · Andrew L. Coveler, Matthew J. Reilley, et al. · Clinical Cancer Research · 34
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report
2023 · Dong-Wan Kim, Sang-We Kim, et al. · Journal of Thoracic Oncology · 32
PDF
Clinical Significance and Role of TK1, CEA, CA 19-9 and CA 72-4 levels in Diagnosis of Colorectal Cancers
2020 · Swarnima Singh, Rakesh Kumar, et al. · Asian Pacific Journal of Cancer Prevention · 30
PDF
Efficacy of cyclosporine as a single agent therapy in chronic idiopathic thrombocytopenic purpura
2008 · D.R. Choudhary, R. Naithani, et al. · Haematologica · 26
PDF
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer
2024 · Gerald S. Falchook, James Reeves, et al. · Cancer Immunology Immunotherapy · 23
PDF
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer
2024 · Neil H. Segal, Jeanne Tie, et al. · British Journal of Cancer · 22
LBA42 COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC
2021 · A. Martinez-Marti, M. Majem, et al. · Annals of Oncology · 21
916MO Safety and efficacy of MEDI0457 plus durvalumab in patients (pts) with human papillomavirus-associated recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC)
2020 · C. Aggarwal, N.F. Saba, et al. · Annals of Oncology · 21
Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model
2021 · Veronika Voronova, Kirill Peskov, et al. · Frontiers in Immunology · 18
PDF
Works count: 133
Citation count: 2,280
H-index: 22
I10-index: 29
Year
Topic
Type